CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness

Similar documents
Clinical Review Report (Sample)

Service Line: Rapid Response Service Version: 1.0 Publication Date: January 21, 2019 Report Length: 5 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: June 12, 2018 Report Length: 5 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: March 5, 2018 Report Length: 5 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: October 30, 2018 Report Length: 7 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: August 30, 2018 Report Length: 11 Pages

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 09, 2018 Report Length: 7 Pages

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

Service Line: Rapid Response Service Version: 1.0 Publication Date: April 4, 2018 Report Length: 14 Pages

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

Increasing Frequency of Self-Monitoring Blood Glucose Test Strips During Pregnancy: A Review of the Clinical and Cost- Effectiveness and Guidelines

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

CADTH Therapeutic Review

DATE: 17 July 2012 CONTEXT AND POLICY ISSUES

TITLE: Discontinuation of Benzodiazepines and Other Sedative-Hypnotic Sleep Medication in Hospitalized Patients: Clinical Evidence and Guidelines

CADTH Canadian Drug Expert Committee Recommendation

CADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report

TITLE: Hyperbaric Oxygen Therapy for Adults with Mental Illness: A Review of the Clinical Effectiveness

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Benzydamine for Acute Sore Throat: A Review of Clinical Effectiveness and Guidelines

TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines

CADTH Canadian Drug Expert Committee Recommendation

BRAF Targeted Therapy for Patients with Melanoma and Active Brain Metastases: A Review of Clinical Effectiveness

CADTH Canadian Drug Expert Committee Recommendation

TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness and Guidelines

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

TITLE: Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines

Insulin Pens in Acute Care Settings: Clinical Effectiveness, Cost- Effectiveness, and Guidelines

CADTH HEALTH TECHNOLOGY ASSESSMENT Screening for Hepatitis C Virus: A Systematic Review

CADTH Canadian Drug Expert Committee Recommendation

Service Line: Rapid Response Service Version: 1.0 Publication Date: October 18, 2017 Report Length: 20 Pages

DATE: 04 April 2012 CONTEXT AND POLICY ISSUES

Health Interventions in Ambulatory Cancer Care Centres DRAFT. Objectives. Methods

Pharmacoeconomic Review Report

TITLE: Probenecid Dosing When Given with Cefazolin: Guidelines and Clinical Effectiveness

TITLE: Left Atrial Appendage Occlusion: Economic Impact and Existing HTA Recommendations

CADTH TECHNOLOGY REVIEW Current Practice Analysis: Interventions for Insomnia Disorder

Service Line: Rapid Response Service Version: 1.0 Publication Date: February 15, 2017 Report Length: 15 Pages

CADTH Canadian Drug Expert Committee Recommendation

TITLE: Immediate Osseointegrated Implants for Cancer Patients: A Review of Clinical and Cost-Effectiveness

TITLE: Naltrexone for the Treatment of Alcohol Dependence in Individuals with Co- Dependencies: A Review of the Clinical Effectiveness

CADTH Canadian Drug Expert Committee Recommendation

Service Line: Rapid Response Service Version: 1.0 Publication Date: August 31, 2018 Report Length: 10 Pages

TITLE: Use of Bupropion in Patients with Depression and the Associated Risk of Seizures: Safety

Common Drug Review Pharmacoeconomic Review Report

Orthodontic Treatment for the Management of Pain or Impacted Teeth in Patients with Malocclusion: A Review of Clinical Effectiveness and Guidelines

TITLE: Critical Incident Stress Debriefing for First Responders: A Review of the Clinical Benefit and Harm

CADTH Optimal Use Report

Title: Re-using the Canister Portion of Metered Dose Inhalers in a Hospital Setting: Clinical Review of Safety, Cost-Effectiveness and Guidelines

CADTH Canadian Drug Expert Committee Recommendation

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES:

Service Line: Rapid Response Service Version: 2.0 Publication Date: November 29, 2018 Report Length: 20 Pages

This report will provide a review on the comparative clinical effectiveness and safety between intranasal triamcinolone and beclomethasone.

Health Interventions in Ambulatory Cancer Care Centres

Date: 23 June Context and policy issues:

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 04, 2018 Report Length: 19 Pages

TITLE: Dose of Electrical Current for Biphasic Defibrillators for Synchronous Cardioversion in Patients with Tachyarrhythmia: Guidelines

DATE: 22 May 2013 CONTEXT AND POLICY ISSUES

TITLE: Type of Thermometer for Inpatients: Clinical-Effectiveness and Guidelines

Behaviour Modification for the Treatment of Urinary Incontinence Resulting from Neurogenic Bladder: A Review of Clinical Effectiveness and Guidelines

TITLE: Vacuum Boards for Spinal Motion Restriction: Clinical Effectiveness

CADTH TECHNOLOGY REVIEW Community Water Fluoridation Programs: A Health Technology Assessment Review of Dental Caries and Other Health Outcomes

TITLE: Closed Catheter Systems for Prevention of Urinary Tract Infections: A Review of the Clinical Effectiveness

COMPUS Vol 2, Issue 8 December 2008

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

Title: Scoop Stretcher for Restriction of Spinal Motion: Clinical Effectiveness

Common Drug Review Pharmacoeconomic Review Report

Clinical Review Report

TITLE: Hyperbaric Oxygen Therapy for Autism: A Review of the Clinical and Cost- Effectiveness

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 04, 2018 Report Length: 47 Pages

TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms

TITLE: Shilla and MAGEC Systems for Growing Children with Scoliosis: A Review of the Clinical Benefits and Cost-Effectiveness

Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review

TITLE: Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines

CADTH OPTIMAL USE REPORT HPV Testing for Primary Cervical Cancer Screening Project Protocol

Title: Shortened Dental Arch and Restorative Therapies: Evidence for Functional Dentition

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 19, 2017 Report Length: 66 Pages

Metastatic Melanoma Gap Analysis: Protocol

pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018

TITLE: Universal, Community-Based Developmental Screening Tools for Children 6 Years and Younger: A Review of Clinical Effectiveness

DATE: 21 November 2012 CONTEXT AND POLICY ISSUES

TITLE: Gabapentin for HIV-associated Neuropathic Pain: A Review of the Clinical Effectiveness

Title: Elective Endovascular Abdominal Aortic Aneurism Repair versus Open Surgery: A Clinical and Cost Effectiveness Review

Service Line: Rapid Response Service Version: 1.0 Publication Date: December 14, 2018 Report Length: 45 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: September 25, 2017 Report Length: 28 Pages

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

GRADE Evidence Profiles on Long- and Rapid-Acting Insulin Analogues for the treatment of Diabetes Mellitus [DRAFT] October 2007

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

The MASCC Guidelines Policy

CADTH Technology Report

Approaches to Diagnosing Acute Pulmonary Embolism in Canada: Current Practice, Challenges, and Availability of Testing

CADTH TECHNOLOGY REVIEW Metastatic Melanoma Gap Analysis

TITLE: Memantine in Combination with Cholinesterase Inhibitors for Alzheimer s Disease: Clinical Effectiveness

Inpatient and Outpatient Treatment Programs for Substance Use Disorder: A Review of Clinical Effectiveness and Guidelines

Mismatch Repair Deficiency Testing for Patients with Colorectal Cancer: A Clinical and Cost-Effectiveness Evaluation

PLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.

Scientific Working Group on Digital Evidence

Transcription:

CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness Service Line: Rapid Response Service Version: 1.0 Publication Date: August 14, 2018 Report Length: 5 Pages

Authors: Wendy Pejic, Suzanne McCormack Cite As: Side effect free chemotherapy for the treatment of cancer: clinical effectiveness. Ottawa: CADTH; 2018 Aug. (CADTH rapid response report: reference list). Acknowledgments: Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH. CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials. This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites. Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada s federal, provincial, or territorial governments or any third party supplier of information. This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user s own risk. This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors. About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system. REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer 2

Research Question What is the clinical effectiveness of side-effect-free chemotherapy for the treatment of any type of cancer? Key Findings No relevant literature was identified regarding the clinical effectiveness of side-effect-free chemotherapy for the treatment of any type of cancer. Methods A limited literature search was conducted on key resources including OVID Medline, Embase, PubMed, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD), Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between Jan 1, 2010 and Aug 3, 2018. Internet links were provided, where available. Selection Criteria One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1. Table 1: Selection Criteria Population Intervention Patients (adults and children) with any type and stage of cancer SEF (side effect-free) chemotherapy (defined as a regimen of carboplatin and mesna as the primary agents) Comparators Conventional standard of care for the given cancer (e.g., chemotherapy, surgery, radiation); Placebo Outcomes Response rate; Survival (progression free survival, overall survival); Quality of life; Toxicity; Adverse events Discontinuation Study Designs Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, nonrandomized studies REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer 3

Results No relevant health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, or non-randomized studies were identified regarding the clinical effectiveness of side-effect-free chemotherapy for the treatment of any type of cancer. One reference of potential interest is provided in the appendix. Health Technology Assessments Systematic Reviews and Meta-analyses Randomized Controlled Trials Non-Randomized Studies REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer 4

Appendix Further Information Non-Randomized Studies Combination of Carboplatin, Ifosfamide, and Mesna were Not Identified as Side- Effect-Free Chemotherapy 1. Dandamudi RK, Aslam S, Walji N, El-Modir A, Fernando I. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna. Anticancer Res. 2015 Sep;35(9):4841-4847. PubMed: PM26254376 REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer 5